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Introduction 
Dermatomyositis is an idiopathic inflammatory 
myopathy characterized by proximal skeletal muscle 
weakness and muscle inflammation that can be 
challenging for providers to diagnose [1]. Myositis-
specific antibodies including nuclear matrix protein 
(NXP-2) have emerged as a valuable tool to support 
clinical features and facilitate timely diagnosis [2-3]. 
NXP-2 antibodies are more common in younger, 
Caucasian patients, and are most frequently 
associated with calcinosis cutis in juvenile 
dermatomyositis [4]. NXP-2 antibodies may also 
indicate a poorer prognosis despite milder 
cutaneous features [5]. Herein, we present an adult 
patient with NXP-2-positive dermatomyositis and 
review relevant clinical features of NXP-2-positive 
dermatomyositis and treatment algorithms for 
disease management. 
 
Case Synopsis 
A 22-year-old man presented with two months of 
fatigue, back and neck pain, and joint pain most 
prominent in his knees, shoulders, and ankles. He 
was referred to dermatology clinic for evaluation of a 
rash on his elbows, neck, and face. Physical 
examination revealed multifocal erythematous 
plaques with violaceous papules located on the 
bilateral elbows (Figure 1A), right popliteal fossa, 
neck (Figure 1B), and bilateral face, more prominent 
on the right than the left side. The patient began 
triamcinolone 0.1% cream and hydrocortisone 2.5% 
cream twice daily. Two punch biopsies were 
performed, one of a lesion on the left elbow and 
another of the upper back. 
The biopsies revealed interface dermatitis (Figure 
2A). Both specimens demonstrated similar findings 
including focal vacuolar interface dermatitis, 
basement membrane thickening, and prominent 
dermal mucin deposition (Figure 2B). The 
constellation of findings was noted to be most 
consistent with connective tissue disease. The 
specimen from the left elbow was also noted to have 
focal leukocytoclasis suggestive of early 
leukocytoclastic vasculitis. Given these findings, a 
Abstract 
Dermatomyositis is a clinically heterogenous 
inflammatory myopathy with unique cutaneous 
features. Myositis-specific antibodies can aid in 
diagnosis and anticipation of patient prognosis. 
Herein, we report a 22-year-old man who presented 
with multifocal erythematous plaques with 
violaceous papules on his bilateral elbows, neck, and 
face. He was diagnosed with biopsy-proven 
dermatomyositis and determined to be seropositive 
for nuclear matrix protein 2 antibody (NXP-2). He was 
treated with systemic corticosteroids, then 
intravenous methylprednisolone and azathioprine, 
and ultimately achieved greatest treatment response 
with intravenous immune globulin therapy. 
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prednisone taper was initiated for a presumed 
autoimmune connective tissue disease. 
The patient’s C-reactive protein was elevated at 3.9 
(normal range <3mg/L) though his erythrocyte 
sedimentation rate was within normal limits. His 
cryoglobulin was negative and his rheumatoid factor 
was unremarkable. Laboratory analysis was 
significant for a positive anti-chromatin antibody, 
positive antinuclear antibody screen multiplex, and 
increased NXP-2 antibodies confirming a diagnosis 
of dermatomyositis. 
The patient reported his myalgia and joint pain 
improved with prednisone, but he began to have 
trouble swallowing. However, the primary team did 
not elect to perform a barium swallow or 
esophagogastroduodenoscopy. Laboratory analysis 
revealed elevated creatine kinase at 2,544 (normal 
range 30-220U/L) and aldolase elevated at 35 
(normal range less than or equal to 8.1U/L). His 
hepatic function panel was significant for an 
elevated ALT of 79 (normal range 10-52U/L) and AST 
of 164 (normal range 14-40U/L). His C3/C4 
complement, hepatitis panel, and serum protein 
electrophoresis were unremarkable. 
Needle electromyography was performed on 
muscles of the right extremities and revealed 
spontaneous fibrillation potentials and positive 
sharp waves in proximal muscles consistent with 
myositis. He began intravenous methylprednisolone 
therapy and then was started on azathioprine 50mg 
with sulfamethoxazole trimethoprim 160mg to 
decrease infection risk. The patient discontinued the 
sulfamethoxazole trimethoprim owing to an allergic 
reaction. Given the constellation of clinical 
symptoms and positive NXP-2 antibodies, 
paraneoplastic dermatomyositis was considered. 
Subsequent testicular ultrasound revealed no 
appreciable changes or abnormalities. A CT of the 
abdomen and pelvis was also unremarkable. 
Ultimately, the patient began intravenous immune 
globulin (IVIG) therapy. At his two-month 
dermatology clinic follow-up visit the patient 
reported marked improvement. Scaling of the 
patient's face resolved, though the rash was still 
visible on his elbows and neck. Although his work-up 
for malignancy has been negative to-date we will 
continue to monitor. 
 
Case Discussion 
Myositis-specific antibodies have emerged as a 
valuable laboratory test for patients in which the 
clinical diagnosis of dermatomyositis is equivocal. 
Nuclear matrix protein-2 antibodies are believed to 
regulate RNA metabolism and transcription, which 
contributes to various nuclear functions [6]. 
Importantly, NXP-2 antibodies are more common in 
juvenile dermatomyositis [7], despite our patient 
representing a case of adult dermatomyositis. 
Although children with juvenile dermatomyositis 
typically lack underlying malignancy, NXP-2-positive 
  
Figure 1. A) Clinical photo demonstrating multifocal 
erythematous plaques with violaceous papules located on the 
bilateral elbows, consistent with Gottron papules. B) Clinical 
photo demonstrating erythematous plaques on the patient’s 
posterior neck of morphology consistent with the shawl sign. 
A 
B 
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dermatomyositis is strongly associated with 
malignancy in adults [8]. 
A retrospective cohort analysis by Rogers et al. found 
that NXP-2-positive adult dermatomyositis patients 
often have a distinct clinical phenotype with more 
severe systemic involvement despite milder 
inflammatory skin disease. Of note, adult patients 
were more likely to experience myalgia, peripheral 
edema, and significant dysphagia, whereas patients 
were less likely to exhibit pathognomonic findings 
such as Gottron papules or the “shawl sign” [9]. 
Interestingly, on physical examination our patient 
exhibited Gottron papules on his elbows and the 
shawl sign on his neck. He also experienced 
significant myalgia and dysphagia, yet he lacked 
peripheral edema or underlying malignancy. 
Regardless, patients with NXP-2-positive adult 
dermatomyositis require more aggressive treatment 
than adult patients lacking NXP-2 seropositivity. For 
adult patients with NXP-2-positive dermatomyositis, 
age-appropriate screening and symptom-targeted 
malignancy screening may be insufficient in 
detecting underlying malignancy. Thus, patients 
may require full-body imaging with MRI, CT, or PET-
CT [10-12]. 
In contrast, NXP-2-positive juvenile dermatomyositis 
is more often associated with calcinosis cutis [4, 13] 
and patients present commonly with severe 
myopathy [5]. Patients may develop gastrointestinal 
bleeding owing to vasculopathy secondary to 
muscle ischemia, though systemic involvement is 
otherwise less common [7]. Age-appropriate 
screening and symptom-targeted malignancy 
screening are typically sufficient for juvenile 
dermatomyositis given the decreased likelihood of 
underlying malignancy. Thus, knowledge of NXP-2 
seropositive adult dermatomyositis versus juvenile 
dermatomyositis is essential in anticipating clinical 
sequelae and determining prognosis. 
Initial management of NXP-2-positive adult 
dermatomyositis depends on lesion type, degree of 
muscle involvement, presence of systemic 
symptoms, and specific patient age [12]. For adult 
patients with non-vasculopathic cutaneous disease, 
sun protection, topical corticosteroids, and systemic 
therapies represent a first-line triad [12]. Systemic 
therapies may include corticosteroids, antimalarials, 
methotrexate or mycophenolate mofetil, and 
rituximab depending on extent of disease. 
Intravenous immune globulin therapy may be 
indicated in patients who fail conventional therapies 
or in whom myopathy is controlled but cutaneous 
disease is persistent. Emerging therapies include JAK 
kinase inhibitors such as tofacitinib [14]. 
Similarly, the initial management of juvenile 
dermatomyositis consists of high dose 
corticosteroids with either oral or intravenous 
methotrexate [15]. Dermatologists and 
rheumatologists may also consider adjuvant 
therapies including cyclosporine or rituximab. The 
Pediatric Rheumatology International Trials 
Organization (PRINTO) was a large, international, 
randomized, open-label trail which found that dual 
therapy with prednisone and either cyclosporine or 
methotrexate was more efficacious than prednisone 
monotherapy [16]. Additionally, the study 
determined the safety profile and steroid-sparing 
effect favored the combination of prednisone plus  
  
Figure 2. A) H&E histopathology of dermatomyositis 
demonstrating focal vacuolar interface dermatitis and basement 
membrane thickening, 200×. B) Histopathology of 
dermatomyositis showing prominent dermal mucin deposition. 
H&E, 200×. 
A 
B 
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methotrexate dual therapy. In general, providers 
should aim to mitigate corticosteroid exposure to 
pediatric patients [15]. Currently, there is a paucity of 
evidence as to which treatment regimens are most 
efficacious depending on myositis-specific antibody 
seropositivity. 
 
Conclusion 
Dermatomyositis in an idiopathic inflammatory 
myopathy, which may be difficult to diagnose given 
its heterogeneity in clinical presentation. The use of  
myositis-specific antibodies, such as NXP-2, and a 
thorough understanding of the relative differences 
between juvenile and adult dermatomyositis can be 
helpful in optimizing clinical evaluation and 
anticipating prognosis. Further research is needed to 
determine if individual myositis-specific antibody 
dermatomyositis phenotypes respond differently to 
certain treatment modalities. 
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